Abstract:Background Hereditary spastic paraplegias (HSPs) are a group of genetically heterogeneous neurodegenerative disorders characterized primarily by progressive spasticity and weakness in the lower limbs. Our objective was to determine the clinical and molecular characteristics of patients with genetically confirmed childhood-onset HSPs and to expand the genetic spectrum for some rare subtypes of HSP. Methods We reviewed the charts of subjects with genetically confirmed childhood-onset HSP. The age at the disease onset was defined as the point at which the delayed motor milestones were observed. Delayed motor milestones were defined as being unable to hold the head up by four months, sitting unassisted by nine months, and walking independently by 17 months. If there were no delayed motor milestones, age at disease onset was determined by leg stiffness, frequent falls, or unsteady gait. Genetic testing was performed based on delayed motor milestones, progressive leg spasticity, and gait difficulty. The variant classification was determined based on the American College of Medical Genetics (ACMG) standard guidelines for variant interpretation. Variants of uncertain significance (VUS) were considered disease-associated when clinical findings were consistent with the previously described disease phenotypes for pathogenic variants. In addition, in the absence of another pathogenic, likely pathogenic, or VUS variant that could explain the phenotype of our cases, we concluded that the disease is associated with VUS in the HSP-causing gene. Segregation analysis was also performed on the parents of some patients in order to demonstrate the inheritance model. Results There was a total of 18 patients from 17 families. The median age of symptom onset was 18 months (2 to 84 months). The mean delay between symptom onset and genetic diagnosis was 5.8 years (5 months to 17 years). All patients had gait difficulty caused by progressive leg spasticity and weakness. Independent walking was not achieved at 17 months for 67% of patients (n = 12). In our cohort, there were two subjects each with SPG11, SPG46 and SPG 50 followed by single subject each with SPG3A, SPG4, SPG7, SPG8, SPG30, SPG35, SPG43, SPG44, SPG57, SPG62, IAHSP, and SPPRS. Eight novel variants in nine patients were described. Two affected siblings had a novel variant in the GBA2 gene (SPG46), and one subject each had a novel variant in WASHC5 (SPG8), SPG11 (SPG11), KIF1A (SPG30), GJC2 (SPG44), ERLIN1 (SPG62), ALS2 (IAHSP), and HACE1 (SPPRS). Among the novel variants, the variant in the SPG11 was pathogenic, and the variants in the KIF1A , GJC2 , and HACE1 were likely pathogenic. The variants in the GBA2, ALS2, ERLIN1 , and WASHC5 were classified as VUS. Conclusion There was a significant delay between symptom onset and genetic diagnosis of HSP. An early diagnosis may be possible by examining patients with delayed motor milestones, progressive spasticity, gait difficulties, and neuromuscular weakness in the context of HSP. Eight novel variants in nine patients were described, clinically similar to the previously described disease phenotype associated with pathogenic variants. This study contributes to expanding the genetic spectrum of some rare subtypes of HSP.

Hereditary spastic paraplegia type 35 in a Turkish girl with fatty acid hydroxylase-associated neurodegeneration

A rare family with Hereditary Spastic Paraplegia Type 35 due to novel FA2H mutations: a case report with literature review.

Novel Homozygous FA2H Variant Causing the Full Spectrum of Fatty Acid Hydroxylase-Associated Neurodegeneration (SPG35)

A novel homozygous deletion including exon 1 of FA2H gene cause spastic paraplegia-35: genetic and lipidomics analysis of the patients

SPTAN1 Variants Likely Cause Autosomal Recessive Complicated Hereditary Spastic Paraplegia

Clinical phenotype and genotype analysis of hereditary spastic paraplegia type 35

Receptor Expression-Enhancing Protein 1 Gene (SPG31) Mutations Are Rare in Chinese Han Patients with Hereditary Spastic Paraplegia.

Novel Mutations in the SPAST Gene Cause Hereditary Spastic Paraplegia.

A retrospective review of 18 patients with childhood-onset hereditary spastic paraplegia, nine with novel variants

Early-Onset and Severe Complex Hereditary Spastic Paraplegia Caused by De Novo Variants in SPAST

A pseudo‐homozygous missense variant and Alu‐mediated exon 5 deletion in FARS2 causing spastic paraplegia 77

Clinical Phenotype and Genetic Mutation of Fatty Acid Hydroxylase - Associated Neurodegeneration: Analysis of Four Cases

SPG35 Contributes to the Second Common Subtype of AR‐HSP in China: Frequency Analysis and Functional Characterization of FA2H Gene Mutations

Two Sibling Cases of Spastic Paraplegia-45 with a Novel Pathogenic Variant in NT5C2 Gene: Concomitant RYR1 Gene in One Sibling

Novel Mutations in Endoplasmic Reticulum Lipid Raft-associated Protein 2 Gene Cause Pure Hereditary Spastic Paraplegia Type 18

Case Report: Hereditary Spastic Paraplegia with a Novel Homozygous Mutation in ZFYVE26

Tremor as an early sign of hereditary spastic paraplegia due to mutations in ALDH18A1

A Newly Identified Missense Mutation in FARS2 Causes Autosomal Recessive Spastic Paraplegia.

Investigating the genetic basis of hereditary spastic paraplegia and cerebellar Ataxia in Pakistani families

Previously Undescribed Gross HACE1 Deletions as a Cause of Autosomal Recessive Spastic Paraplegia

Hereditary spastic paraparesis type 46 (SPG46): new GBA2 variants in a large Italian case series and review of the literature